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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Midazolam is a widely used sedative agent during colonoscopy, with
cognitive toxicity. However, the potential cognitive hazard of midazolam-based light sedation
has not been sufficiently examined. We aimed to examine the cognitive safety and vulnera-
bility profile under midazolam light sedation, with a particular focus on individual variations.
Methods: We conducted a prospective case-controlled study in an academic hospital. In total,
30 patients undergoing sedative colonoscopy as part of a health check-up were recruited. Neu-
ropsychological testing on the full cognitive spectrum was evaluated at 15 minutes and 120 mi-
nutes after low-dose midazolam administration. The modified reliable change index (RCI) was
used for intrapersonal comparisons and controlling for practice effects.
Results: Midazolam affected psychomotor speed (48%), memory (40%), learning (32%), working
memory (17%), and sustained attention (11%), while sparing orientation and the fluency aspectof Psychology, National Taiwan University, Number 1, Section 4, Roosevelt Road, Taipei 100, Taiwan.
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490 Y.-H. Hsu et al.of executive function at the acute stage. Residual memory (10%) and learning (10%) impair-
ments at 2 hours after administration were evidenced in some patients. The three object recall
and digit symbol coding tests can serve as useful screening tools.
Conclusion: Midazolam-based light sedation induced selective cognitive impairments and pro-
longed cognitive impairments occurred in patients with advanced age. A longer observation
time and further screening were recommended for patients due to their at risk state.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Midazolam is frequently used as a sedative agent for its
hypnotic and amnestic properties. Despite a return to full
alertness at discharge, patients may remain cognitively
impaired.1,2 It is thus important to understand the time
frame of cognitive change under midazolam.
In endoscopic operations, sedative premedication can
be used to achieve patient comfort, followed by a rapid
recovery of consciousness and orientation when an appro-
priate dose is administered.3,4 Patients under light sedation
usually return to work or home after a brief hospital stay.
Although they are discharged being alert and vigilant, ac-
cording to the discharge criteria, it is questionable whether
they are cognitively functional at their customary level.
There are at least two limitations of previous studies that
investigated this issue. First, literature of midazolam
sedation during endoscopic procedures concentrated on
psychomotor speed and memory function.1e9 However,
other cognitive impairments, such as attention and working
memory, may also appear and affect the ability to cope
with current environmental demands. Different cognitive
changes require different ways of adaptation and
compensation. The full spectrum of cognitive functioning is
nonetheless of particular interest, considering the
complexity of human cognition. By contrast, the search of
screening test tools for adverse cognitive side-effects will
render valuable clinical information, because it is not al-
ways viable to administrate a comprehensive cognitive
examination in routine clinical practice.
Second, although a few comprehensive neuropsycho-
logical studies have been done on patients undergoing
dental treatments under sedation, with various time
intervals,1e10 these studies drew conclusions based on
group mean comparisons that unnecessarily detected
cognitive changes in individual patients.11 The effect of
repetitive practice on cognitive test performance also was
overlooked. A failure to correct these practice effects
reduced the likelihood of detecting a decline between
follow-ups,11,12 possibly leading to false-negative conclu-
sions of sedation-related cognitive impairments.
Jacobson and Truax13 proposed a method in which a
patient’s observed test-retest change score (x2x1) is
divided by the standard error of difference between two
scores (SEdiff) and compared to a “reliable change index
(RCI)”, which is constructed to objectively define the limits
of individual change that exceed base-rate fluctuations and
truly reflect a clinical change. Chelune and colleagues12
further modified the original RCI to control practice ef-
fects resulting from repeated cognitive testing, bysubtracting a constant (average performance change in
control group) from all of the observed scores. This method
has been proven to be as accurate as the more complex
regression models in detecting change in individuals,14 and
has been used in studies with different clinical groups, such
as postoperative cognitive dysfunction of patients after a
cardiac artery bypass graft,15,16 cognitive impairments
after epilepsy surgery,12 and treatment outcomes of Par-
kinson’s Disease.17 It is thought to be more valid and
theoretically sound for defining cognitive changes than the
traditionally used fixed methods,15 especially considering
the large individual variability in terms of drug effects.
The present study aimed to examine the cognitive
impact of midazolam-based light sedation in ambulatory
colonoscopy. We planned to conduct comprehensive neu-
ropsychological examinations for the full cognitive spec-
trum, while endeavoring to control practice effects and
emphasizing individual differences in an attempt to answer
the following questions: (1) Are patients who are
consciously clear actually cognitively intact after mid-
azolam light sedation? (2) What is the cognitive vulnera-
bility profile under midazolam action? and (3) How do we
screen for at risk patients in the bedside?
Patients and methods
Participants
The enrolled participants were patients who gave written
informed consent and received anesthesia during outpa-
tient colonoscopy examinations as part of their health
checkup at the Health Management Center of National
Taiwan University Hospital in 2004. Exclusion criteria
included ASA Class III or greater, history of colonic or rectal
resection, acute gastrointestinal bleeding, any neurological
deficit, an allergy to any of the sedative agents, and history
of regular sedative drug use. A non-sedated and non-
operated control group was also recruited from a commu-
nity base and gave written informed consent. This study
was approved by the ethics committees of National Taiwan
University Hospital.
Study design
All participants received an intravenous injection of
midazolam titrated to produce sedation. Comprehensive
neuropsychological assessments were administrated prior
to the operation (baseline), and at 15 minutes and 120
minutes after midazolam injection in the recovery room
Cognitive impairment after light sedation 491prior to discharge. At each assessment, the administra-
tion time of all neuropsychological tests was about 20
minutes.
The control group did not receive any operation or
sedative treatment. After receiving the first assessment,
the second and third assessments were performed 100 mi-
nutes and 200 minutes afterwards, matched to the mean
intervals of the patient groups (105  21 minutes between
the first and the second assessment; 204  29 minutes
between the first and the third assessment).Neuropsychological testing
We adopted well-established neuropsychological tests to
ensure standardized procedure during data collection.
Mini-Mental State Examination We used the Chinese vers-
ion18 of the Mini-Mental State Examination (MMSE) to test
general cognitive ability.19 The orientation test items
were sorted out as the orientation index (ORI); the score
on serial seven subtractions (SRL) was used as a working
memory index; and the three object recall (3OR) was
adopted as a measure of immediate recall ability (three
different sets of objects were used in each assessment).
The score range was 0e10, 0e5, and 0e3, respectively.
Digit Symbol Substitution Test Participants were asked to
write down symbols that were paired to Arabic numerals
(1e9) on a sheet of digital array as fast as they could in this
Digit Symbol Substitution Test (DSS). Reference of the digit-
symbol pairs was offered on the same sheet.20 The number
of symbols completed within 90 seconds was transformed to
a scaled score (DSS-SS) and served as the psychomotor
speed index. In order to administrate the subsequent
delayed recall test, participants were required to fill in
all the blank spaces. The 10-minute delayed Free Recall
(DSS-FR) and Cued Recall (DSS-CR) tests of the nine
symbols were then given to assess delayed recall
abilities.21 The possible score ranges of the DSS-SS, DSS-
FR, DSS-CR are 1e19, 1e9, and 1e9, respectively.
The Category Fluency Test In the Category Fluency Test
(CFT), participants were asked to generate as many ex-
amples of a given category (fruit, fish, and vegetables) as
possible within 1 minute. This task measures the ability to
strategically retrieve categorical items from semantic
knowledge,22 and is an index of executive function.23
Serial Digit Learning Test The Serial Digit Learning Test
(SDLT) assesses new learning and information processing
ability.24 Participants were required to remember a 12-
digit string repetitively either until they had correctly
recalled it for two consecutive trials, or had been
through 12 trials.25 Three parallel forms of digit lists
were available. The score range was 0e24.
Paced Auditory Serial Addition Test In the Paced Auditory
Serial Addition Test (PASAT), participants were required to
add pairs of adjacent digits presented every 1.6 seconds
through an audio tape, and to respond orally immediately.
We use a modified version containing 25 digits in each trial.This task tests sustained attention.24 The score range was
0e25.
Statistical analysis
We analyzed the data using a modified RCI method, which
focuses on intrapersonal pre-post operational comparison
and controls for practice effects.12 The original RCI method
constructed an interval to objectively define the limits of
individual change that exceeded base-rate fluctuations and
truly reflected a clinical change.13 A participant’s observed
test-retest change score (x2x1) was divided by the stan-
dard error of difference between two scores (Sdiff) and
compared to this “reliable change” interval. According to
Jacobson and Truax, 13 “The formula of RC index is as
following:
Reliable ChangeZ
x2  x1
Sdiff
where x1 represents a subject’s pretest score, x2 rep-
resents that same subject’s posttest score, and Sdiff is the
standard error of difference between the two test scores.
The formula of Sdiff is as following:
SdiffZ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2ðSEÞ2
q
; SEZ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 rxx
p
where SE represents standard error of measurement; and
rxx represents the pre-post test scores correlation.”
The modified RCI controls practice effects by subtracting
a constant (average performance change in the control
group) from all of the observed scores; the distribution of
observed change scores is corrected for the systematic
bias, while approximating the predicted distribution of
change scores in this regard.12 We computed 95% reliable
change intervals for each neuropsychological test score,
and the percentage of intrapersonal performance change
was calculated. The formula of the modified RCI is as
follows:
Modified 95% reliable change intervalZ

SEdiff
ð  1:96Þ
þ practice effect
We also conducted group mean analysis in order to
compare the results with previous studies. Mean values for
patients’ demographic characteristics were compared be-
tween groups by independent t tests and analysis of vari-
ance (ANOVA). Neuropsychological testing scores were
compared with mixed designed ANOVA, the Split-Plot
factorial design, which contains a mixture of both be-
tween- and within-group variables. In our study, the
between-group effect accounts for the effect of drug
treatment and the within-group effect accounts for
repeated measurements. Simple effects of drug treatment
were examined by Tukey HSD when main effects were
found. Type one error, alpha value, was set at 0.05.
Results
In total, 32 eligible participants entered the study. Thirty of
these finished all neuropsychological examinations and
were included in the analysis. Participants received an
average 68.1 (SD Z 15.2) mg/kg of intravenous midazolam.
Table 1 Participants’ characteristics.
Midazolam group Control group
Mean (SD) Mean (SD)
Sex (male:female) 16:14 11:14 n.s.
Handedness
(right:left)
29:01 24:01
Age (y) 54.27 (7.87) 55.04 (5.98) n.s.
Education (y) 13.10 (3.90) 13.72 (3.09) n.s.
Body mass index
(BMI)
23.38 (3.59)
Mean dose for
conscious
sedation (mg/kg)
0.06 (0.02)
n.s. Z nonsignificant; SD Z standard deviation.
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492 Y.-H. Hsu et al.No paradoxical response or resedation phenomena were
observed. The control group (n Z 25) was matched to the
patients groups by sex, education, and body weight (Table
1).
In the following, we will first display the results derived
by ANOVA in accordance to the previous studies, and then
contrast them with the finding in focus that was generated
from the modified RCI method.
The results are summarized in Table 2. The percentage
of performance change is shown in Fig. 1. Group mean
analysis of Tukey HSD simple effect comparisons (Table 2)
showed that the midazolam group performed worse than
the control group at 15 minutes posttreatment on the
PASAT (p < 0.01), DSS test (p < 0.001), and 3OR
test (p < 0.0001). Sustained attention, psychomotor speed,
and immediate recall seemed to be vulnerable to mid-
azolam action. By contrast, the compatible performance
level of the midazolam group compared to the control
group was evidenced at all testing times on orientation, SRL
and CFT, revealing cognitive resiliency in orientation,
working memory, and executive function domains. At
120 minutes after midazolam infusion, performance in
all cognitive domains had returned to the baseline level.
The RCI method using 95% confidence intervals and
controlling practice effects revealed a less favorable pic-
ture (Fig. 2). In addition to the large proportion of patients
with performance decline on the vulnerable DSS (48.30%),
3OR (36.70%), and SDLT (32.10%), 16.70% of patients suf-
fered from working memory deficit as measured by the SRL
at the first posttreatment assessment. At 120 minutes after
midazolam infusion, 20% of the patients still suffered from
memory impairments as reflected by the 3OR and SDLT. The
cut-off value of scores on each test at repeated testing are
listed in Table 3.
Practice effects were prominent on tests of sustained
attention, delayed recall, and executive function. Although
the control group seemed to perform better than the
midazolam group at each time point, there was no signifi-
cant interaction between treatment and time of assess-
ment in this measure. Thus, it implied the fluency aspect of
executive function is resilient to midazolam action. These
effects might be due to the heterogeneity of the groups.
They may have been partly affected by certain factors,
Figure 1 Cognitive vulnerability profile shown by percentage of performance change. (A) Patients who received midazolam
sedation had remarkable performance decline in immediate recall, psychomotor speed and sustained attention at 15 minutes after
injection as compared to the control group. There was also a noticeable performance decline in new learning, although the dif-
ference did not achieve statistical significance. (B) There was no significant difference on any test performance between the two
groups at 120 minutes posttreatment.
Cognitive impairment after light sedation 493such as anxiety in response to medical settings and surgical
treatment. The performance of the control group on the
SDLT declined at the third assessment, perhaps due to fa-
tigue, annoyance, or lack of motivation in repetitively
doing this effortful task.Discussion
The cognitive vulnerability profile and recovery time frame
of midazolam in day-case colonoscopy was examined in the
present study, with an effort to control the practice effect
and to highlight the individual variation of drug response.
With regard to the first and second research questions, our
results showed that: (1) remarkable multiple-domain
cognitive impairments were observed at 15 minutes after
midazolam-based light sedation and residual cognitive im-
pairments were still noticed in some patients, whereas they
all seemed alert at 2 hours posttreatment; and (2) psy-
chomotor speed, episodic memory, sustained attention,
working memory, and the fluency aspect of executive
function were vulnerable to midazolam action, andprolonged memory impairments, including new learning
and immediate recall abilities, were evident in some pa-
tients at 2 hours after infusion.
When analyzing the results by group mean statistics, the
present results were consistent with previous findings, that
midazolam affects performances on neuropsychological
tests of attention,1 psychomotor and memory functions,
1,6e8,26 and that no adverse effect was found on executive
function (as revealed by the strategic retrieval aspect in
our study).26 However, our findings of relatively spared
orientation and working memory function were inconsistent
with previous studies.10,27 The higher doses (7.5e55.5 mg
midazolam) that correlated with longer durations of anes-
thesia and the older age of patients (mean ageZ 70 years,
SD Z 13) in a previous study27 may explain the contradic-
tory finding of orientation impairment. As for working
memory, the more difficult task (judging whether each of
the 30 serially presented digits was one of the five digits
previously presented singly) used in previous research may
contribute to the greater functional change they found.10
This also indicated that there is a gradient of the impact
of midazolam on working memory ability.
Figure 2 Percentage of individuals with significant performance change after sedation. (A) At 15 minutes after sedation, almost
half of the patients suffered psychomotor slowing, about a third of them showed performance decline on new learning or im-
mediate recall, and still some had decline on sustained attention, working memory, executive function, and delayed free recall. (B)
At 120 minutes after sedation, performance decline was still observed in 10% of patients in new learning and in another 10% of
patients in immediate recall.
494 Y.-H. Hsu et al.The modified RCI procedure that focuses on individual
difference further revealed a performance decline in
working memory and delayed free recall tests in some pa-
tients at 15 minutes after midazolam infusion. This finding
partially supports the observation of other research, that
working memory was impaired under the midazolam ac-
tion.10 Moreover, the modified RCI also showed that at 120
minutes after infusion, 10% of the patients still suffered
from problems in memory function, including new learning
and immediate free recall.Our finding adds to the existing knowledge that the
acute action of midazolam not only affects the ability of
learning new things, remembering instructions, and effi-
ciently processing information as indicated by past liter-
atures,1,2,5e8 but also interferes with strategic problem-
solving and the ability of temporally storing and managing
information in mind for further manipulation. Our results
also indicated that, although the patients seemed alert and
vigilant in the recovery room, they may still be less capable
of maintaining their focus and attention over prolonged
Table 3 The cut-off values of each test according to the modified reliable change index (RCI) (x stands for baseline score).
RCI for the second assessment at
15 min after baseline
RCI for the second assessment at
120 min after baseline
Cut-off of
performance
decline
Cut-off of
performance
improvement
Cut-off of
performance
decline
Cut-off of
performance
improvement
Orientation index (ORI) x  0.04 x þ 0.44 x  1.41 x þ 1.57
Paced Auditory Serial Addition Test (PASAT) x  3.75 x þ 7.75 x  2.69 x þ 7.86
Digit Symbol Substitution Test (DSS) x  1.35 x þ 6.15 x  3.30 x þ 5.55
Three object recall (3OR) x  1.11 x þ 1.99 x  0.79 x þ 0.95
10-minute Delayed Free Recall (DSS-FR) x  0.99 x þ 1.87 x  1.40 x þ 2.90
10-minute Delayed Cued Recall (DSS-CR) x  1.35 x þ 6.15 x  1.22 x þ 7.30
Serial Digit Learning Test (SDLT) x  7.20 x þ 10.88 x  9.13 x þ 8.88
Serial seven subtractions (SRL) x  1.93 x þ 2.17 x  2.28 x þ 1.95
Category Fluency Test (CFT) x  7.16 x þ 15.32 x  6.55 x þ 18.63
Cognitive impairment after light sedation 495periods of time, especially when facing distractions. This
finding underscores the fact that clear consciousness and
orientation might not reflect the full recovery of a patients’
cognitive functioning.
Among the comprehensive assessment we performed,
residual cognitive impairments were captured by the 3OR
from the MMSE and the SDLT at 120 minutes after mid-
azolam infusion. Considering the time efficiency, the 3OR
will be the most recommended screening procedure for
midazolam-related posttreatment cognitive dysfunction. If
the patient recalled two items less than they could in the
baseline trial prior to sedation, it is highly likely that they
are still cognitively influenced by the midazolam action. We
also noted that there is another group of patients who
suffered from psychomotor slowing, whilst having had
memory function recovered. It is suggested to utilize the
DSST as a screening tool in this subset of patients. This
coding test is also recommended as a substitute for those
who scored zero in the 3OR test in the baseline assessment.
The cut-off points of clinically meaningful performance
decline are listed in Table 3 for reference.
It is possible that midazolam affects cognitive function
by facilitating g-aminobutyric acid type A (GABAA) activity,
through increasing the frequency of specific channel
opening and decreasing hippocampal cholinergic function,
which is essential for memory function.28 We noticed a
differential effect that midazolam induced more profound
memory impacts than psychomotor impairment. We also
found that midazolam distinctively impaired the acquisition
stage of the memory process, rather than the storage and
retrieval stages. This effect could be seen in the fact that
participants performed better on tests with repetitively
used materials than on those with parallel forms, even after
the correction of practice effects. As evidenced in an
earlier report,8 benzodiazepines tended not to disrupt
retention and retrieval of previously-stored information.
The strength of using the modified RCI method is at least
twofold. First, it attempted to quantify the practice effect
and statistically attenuate its influence on study results. This
control of practice effect is important, yet has been over-
looked. Participants’ performance improvement across re-
petitive testing, due to practice, may cover the detrimental
treatment effect, thereby leading to underestimation of thepotential cognitive risk. Second, unlike the group mean
analysis like ANOVA, that neutralizes individual variations,
the modified RCI procedure provides information of actual
intrapersonal comparisons. Instead of summing each pa-
tient’s test score at each assessment into group means to be
compared, the modified RCI method created a 95% reliable
change interval across assessment time, based on the per-
formance of the control group and defined each patient’s
performance as declined (or improved) when the intraper-
sonal performance change was larger than this interval. The
rationale of this statistic manipulation is that some patients
might be less easily affected by anesthetics, because of their
biological predispositions, such as pharmacodynamic and
pharmacokinetic variability between individuals.6 Perfor-
mance improvements or stability in these patients might
have neutralized the decline in patients who were actually
vulnerable to anesthetics and made certain cognitive do-
mains appear unaffected under drug action. The modified
RCI method thus provides a more clinically significant way to
examine test results and avoid underestimation of side-
effects.
The issue of sedation-related cognitive impairment is
important, because safety risk and medico-legal disputes
may ensue. Sedative endoscopy is chosen to achieve pa-
tient comfort and ease of administration, while undesired
cognitive side effects sometimes occur. Patients and rela-
tives should be clearly informed of the possible residual
effects of cognitive changes and instructed to avoid activ-
ities requiring higher cognitive functions that are vulner-
able to sedation during the active period of drug effects,
such as remembering making an appointment, driving
home, and decision-making. A warning from medical staff is
not dispensable because it has been reported that patients
generally did not expect and were not aware that their
memory would be and was compromised by sedation.29 Due
to this lack of awareness, they may not intentionally
generate alternative strategies to cope with environmental
demands and avoid potential hazards.30 Medical practi-
tioners are thus ethically responsible for providing relevant
information to patients and their families beforehand. In
case of medical tangles that derived from a temporal
relationship between sedative procedure and adverse
incidence, cognitive tests can be used to document
496 Y.-H. Hsu et al.patients’ cognitive recovery by the time of discharge. This
action is particularly suggested for patients with advanced
age, as increasing risk of prolonged cognitive impairments
were evident in this study.
There were several limitations in the present studies.
First, practice effects were prominent in some measures of
neuropsychological functions. This may result in a less
sensitive detection of functional decline during repetitive
testing and interference with the interpretation of the
study results. We intended to correct this problem by sta-
tistic control that quantitatively estimated practice ef-
fects; however, some patients might benefit more from
practicing than others, owing to social, educational, moti-
vational, dispositional, or other nuisance factors, making
the group-wise control of practice effects less optimal.
Moreover, in using community-based non-sedated samples
to estimate practice effects, we presumed patients under
sedation would show the same amount of practice effects
as their non-sedated matched group. This presumption is
questionable, considering midazolam may compromise the
tendency to benefit from practicing and thus alleviate or
even eliminate practice effects on some neuropsychologi-
cal test performances in the patient group. Nonetheless,
this limitation seems not to weaken our research mainstay,
because the interpretation has become more conservative
after subtracting the expected practice effects.
Second, the sample size of this present study is rela-
tively small. This limitation is particularly significant in the
use of the modified RCI method. The small sample size led
to a dramatic change in percentile as the actual number of
change increased slowly. A larger sample size is recom-
mended and our results await support from future large-
scale studies. Third, having a relatively small sample size,
we were not able to plan comparisons in order to identify
risk factors of prolonged cognitive impairments after mid-
azolam sedation. The identification of risk factors will help
narrow down the patient type that requires further cogni-
tive examinations. It was indicated by our results that
advanced age was a risk factor of prolonged cognitive im-
pairments. Other factors, such as underlying diseases of
diabetes mellitus and Alzheimer’s disease, pre-sedation
cognitive function level, and educational level, are candi-
dates awaiting investigation in future research. Another
limitation is that the follow-up time in the current study
was relatively short. We were not aware of any resedation
phenomenon during the observation time; however, it
might occur later after discharge.
In summary, the present study revealed that delayed
cognitive recovery up to 2 hours can be seen, even after a
safe light sedation procedure. Every one out of five patients
suffered cognitive impairment at the time of discharge in
our data. Patients may need a longer observation time prior
to discharge. It calls attention for patients’ cognitive
functionality in addition to conscious level, where handy
cognitive tests, such as 3OR or digit symbol coding, can be
utilized to identity those in need of additional care.References
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